Complement factor H autoantibodies are associated with early stage NSCLC

Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC

Nita Amornsiripanitch1, Shaolin Hong1, Michael J. Campa1, Michael M. Frank2, Elizabeth B. Gottlin1, and Edward F. Patz Jr.1,3

Author Affiliations

Corresponding Author: Edward F. Patz, Jr., Duke University Medical Center, Department of Radiology, Box 3808, Durham, NC 27710. Phone: 919-684-7311; Fax: 919-681-7165; E-mail:


Purpose: To discover diagnostic biomarkers associated with early-stage non–small cell lung cancer (NSCLC), we searched for autoantibodies preferentially present in stage I patients compared with patients with advanced-stage disease. Here we describe an autoantibody against complement factor H (CFH) and this autoantibody's association with early-stage NSCLC.


Parc d'activités Activestre
31390 Carbonne - FRANCE


Tél. +33 561 971 974
Fax +33 561 971 975